Navigation Links
Brave Aidan Fraser Heading Home After Lifesaving Surgery

Aiden Fraser, a 6-year-old brave boy, is returning home only a few days after undergoing a rare surgery for removing a tumor that twisted around his spine in Bronx// hospital. The Brooklyn boy, whose father died at the World Trade Center five years ago, suffers from a rare disease called neurofibromatosis, an aggressive disease that causes tumors to grow at the end of nerves.

The Brooklyn boy had wowed doctors with his upbeat spirit saying, “they saved my life”, despite enduring incredible pain and heartbreak. He also said that he would see his dog and get his work done once he is back home.

In the high-risk two-stage operation that took 18 hours, team of 5 doctors at the Bronx’s Montefiore Medical center cut away parts of the tumor, which had caused a grotesque twist in his upper spine, overstretching his spinal cord. They removed the deformed bones in the boy’s neck that had been crushed by the tumor and replaced them with healthy bones that were taken from the ribs.

The doctors said that without an operation, the occasional paralysis experienced by the boy would have become permanent.

Aidan had developed the noncancerous tumor shortly after the death of his father five years ago, making him unable to walk. The biggest challenge for the surgical team was getting through the tumor without damaging the nerves, blood supply and air supply that run through it.

Suzanne Fraser, Aidan's mother, said that her son was a "tough kid" who was doing great and Dr. Adam Levy, a pediatric oncologist, a team member of the operation and the one who brought the Frasers to Montefiore added that the boy was able to walk with assistance from people on each side of him. Dr. Adam Levy coincidentally was a high school classmate of Aidan's father. The entire medical team has planned to support Aidan after his release on Monday.
RI
'"/>




Page: 1

Related medicine news :

1. A ‘Brave’ Toddler-The Youngest Organ Donr
2. ‘Braveheart’- Woman Becomes First to Climb Mountains After Heart Transplat
3. Where Is Our Healthcare System Heading?
4. Young and Obese People Heading for Heart Trouble
5. Cholesterol Drug Helps After Angioplasty
6. Bone Strength After Menopause
7. Indians Stay Away from Coke, Pepsi After Toxin Scare
8. Less Pain After Tonsillectomy
9. Reducing The After Effects of Tonsillectomy
10. PET Scan May Be Beneficial After Cancer Treatment
11. Fertility After Testicular Cancer Questioned
Post Your Comments:
(Date:12/14/2009)... Adults, Attitudes and Behavior Regarding Pregnancy, Contraception, and Related ... Nearly all unmarried young adults ages 18-29 believe pregnancy ... and 86% of women) and say that it is ... (86% of men and 88% of women), according to ... Teen and Unplanned Pregnancy. Even so: ,, ...
(Date:12/14/2009)... oxygen, drugs, and more… , ... ... in collaboration with scientists at University of Michigan, have developed ... of natural red blood cells, including softness, flexibility, and the ... primary function of natural red blood cells is to carry ...
(Date:12/14/2009)... ARBOR, Mich., Dec. 14 Pepsi ... the Commonwealth of Kentucky are among the major ... this fall to help their employees make better ... solution gives employees a personalized summary of their ... of that care. With this personalized information, employees ...
(Date:12/14/2009)... -- Americold Realty Trust ("Americold") announced today that it ... the U.S. Securities and Exchange Commission (the "SEC") relating ... shares. The number of shares to be offered and ... been determined. The common shares to be sold in ... ,, The joint book-running managers of the offering ...
(Date:12/14/2009)... BRAINTREE, Mass., Dec. 14 Haemonetics Corporation ... it has filed a new legal action to ... Fenwal,s just released red cell collection kits, using ... its separation chamber to circumvent Haemonetics, patent and ... continued sale of infringing products after December 1, ...
Breaking Medicine News(10 mins):Health News:Although Most Unmarried Young Adults Want to Avoid Pregnancy, Many Don't Use Contraception, Know Little About It, and Think It Doesn't Make Much Difference 2Health News:Although Most Unmarried Young Adults Want to Avoid Pregnancy, Many Don't Use Contraception, Know Little About It, and Think It Doesn't Make Much Difference 3Health News:Synthetic Red Blood Cells Developed 2Health News:Synthetic Red Blood Cells Developed 3Health News:Corporations, Universities and State Governments Deploy Thomson Reuters Solution to Improve Employees' Benefit Selection Process 2Health News:Americold Realty Trust Files Registration Statement for Proposed Initial Public Offering 2Health News:Haemonetics Files a New Legal Action to Stop Fenwal Inc.'s Continued Patent Infringement 2Health News:Haemonetics Files a New Legal Action to Stop Fenwal Inc.'s Continued Patent Infringement 3
... SAN DIEGO, Nov. 24 Volcano Corporation (Nasdaq: VOLC ... for the diagnosis and treatment of coronary and peripheral artery disease, ... Piper Jaffray Health Care Conference on Tuesday, December 2. , ... and chief executive officer, will begin at 1:30 p.m., Eastern Standard ...
... Calif., Nov. 24 Thoratec Corporation,(Nasdaq: THOR ... to save, support and restore falling hearts, said today ... Jaffray Heath Care Conference on,Wednesday, December 3. , ... provide an,update on the company, beginning at 1 p.m., ...
... Networks, Inc.(TM), the,company delivering new technology in enterprise ... Networks executive Amit Chawla as its new President,and ... Agito Networks, flagship product is the ... IP telephony, and,location information, improving the accessibility and ...
... Leading Specialty Pharmaceutical Company with Greater Commercialization Capabilities, Expanded Portfolio of ... , King Extends Tender Offer Through December 19, 2008 ... BRIDGEWATER, N.J., Nov. 24 King Pharmaceuticals, Inc. (NYSE: ... announced that the two companies have signed a definitive merger agreement ...
... with Broad Potential to Treat Life-Threatening Viral Infections-- , ... and Equivalent Antibodies Cured Lethal Viral Infections in Preclinical Models-- ... is a ,Druggable, Target Common to a Number of Serious ... Calif., Nov. 24 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) ...
... summarized- , , ... Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian ... Cell Wall-DNA Complex (MCC) - trademarked Urocidin - ... 2008 Societe Internationale d,Urologie (SIU) Congress in Santiago, ...
Other Medicine News:Health News:Volcano Corporation Presentation at Piper Jaffray Conference to Be Webcast 2Health News:Agito Networks Names New CEO, Broadens Depth of Experience of Enterprise Mobility Leader 2Health News:Agito Networks Names New CEO, Broadens Depth of Experience of Enterprise Mobility Leader 3Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 2Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 3Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 4Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 5Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 6Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 7Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 8Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 9Health News:Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals' Bavituximab to Cure Lethal Virus Infections 2Health News:Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals' Bavituximab to Cure Lethal Virus Infections 3Health News:Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals' Bavituximab to Cure Lethal Virus Infections 4Health News:Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals' Bavituximab to Cure Lethal Virus Infections 5Health News:Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals' Bavituximab to Cure Lethal Virus Infections 6Health News:Bioniche Presents MCC Data at the SIU World Uro-Oncology Update in Santiago, Chile 2Health News:Bioniche Presents MCC Data at the SIU World Uro-Oncology Update in Santiago, Chile 3
(Date:12/15/2009)... Genomic Health, Inc. (Nasdaq: GHDX ) ... Onco type DX® breast cancer test, a multi-gene ... likelihood of chemotherapy benefit and recurrence risk for patients ... the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium, ... TX. ,, "The breadth of data presented at last ...
(Date:12/15/2009)... Arlington Medical Resources (AMR) and Decision ... (MRSA) is the most concerning pathogen to surveyed ... treatment of skin and skin structure infections. A ... factors that influences European physician drug selection for ... factors that drive prescribing include an agent,s skin ...
(Date:12/15/2009)... INDIANAPOLIS, and CAMBRIDGE, Mass., Dec. 15 ... ), Eli Lilly and Company (NYSE: ... ) today announced positive results from a head-to-head ... therapy, to BYETTA® (exenatide) injection taken twice daily, ... weeks of treatment, patients taking exenatide once weekly ...
Breaking Medicine Technology:Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 2Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 3Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 4Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 5Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 6Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 7A Drug's Activity Against MRSA is Among the Top Factors That Influences European Physician Antibiotic Selection for Treating Skin and Skin Structure Infections 2A Drug's Activity Against MRSA is Among the Top Factors That Influences European Physician Antibiotic Selection for Treating Skin and Skin Structure Infections 3Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 2Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 3Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 4Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 5Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 6Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 7Study Forecasts More Young Doctors in Future 59852 1Study Forecasts More Young Doctors in Future 59852 2Experimental treatments restore partial vision to blind people 10444 1Experimental treatments restore partial vision to blind people 10444 2Minnesota Dentists Warn Halloween Shoppers 3A Sour Candies May Trick Not Treat Teeth 59846 1Minnesota Dentists Warn Halloween Shoppers 3A Sour Candies May Trick Not Treat Teeth 59846 2
... Drugs on the Market and, in Clinical Development with Each ... Anticancer Effects, and Expand the Markets for ... ... Identification of novel,cancer-related targets and pathways is redefining our understanding of ...
... Mich., Feb. 19 Compendia Bioscience, Inc.,today announced ... renewed,and expanding commitment from all major customers and ... to its customer roster. The new,customers and existing ... revenue increase, with similar growth forecasted for 2008., ...
Other Medicine Technology:Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics 2Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics 3Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics 4On Second Anniversary, Compendia Bioscience Announces Significant Revenue Growth, Completion of Product Milestone and Expansion of Pharma Customer Commitments 2On Second Anniversary, Compendia Bioscience Announces Significant Revenue Growth, Completion of Product Milestone and Expansion of Pharma Customer Commitments 3
For the quantitative determination of uric acid in serum....
... new level of immunodiagnostic productivity. Optimal flexibility. ... laboratory automation system. No-pause loading of all ... only immunoassay system with this capability. No ... without any additional setup. Continuous sample loading. ...
... Engineered for continuous, random access operation, the ... medium to large volume laboratories that want ... offers the simplicity, flexibility and Stat capabilities ... can be adapted to the changing needs ...
The Dimension RxL Max is an integrated chemistry system and is the most powerful and technologically advanced Dimension analyze with new standard for excellence in clinical diagnostics. Simply put, t...
Medicine Products: